The contribution of the renin-angiotensin system to the natriuretic responses to intrarenal infusions of 1, 5, 25, and 125 pmol/kg/min synthetic rat atrial natriuretic peptide 101-126 was determined in one-kidney anesthetized dogs. In vehicle-treated dogs, atrial natriuretic peptide 101-126 increased fractional sodium excretion from 1.8 ±0.6% to a peak response of 5.1 ±0.9% during infusion of 25 pmol/kg/min. The peptide progressively decreased mean arterial pressure from 110±5to94±4 mm Hg, renal vascular resistance from 0.40 ± 0.02 to 0.30 ± 0.02 mm Hg/ml/min, and arterial plasma renin activity from 4.3 ±1.6 to 3.1 ±0.8 ng/ml/hr. When the renin-angiotensin system was blocked by 3 mg/kg i.v. enalaprilat, baseline pressure fell to 86 ±4 mm Hg, and subsequent infusions of atrial natriuretic peptide 101-126 did not affect fractional sodium excretion. The decreases in blood pressure (from 86 ± 4 to 76 ± 4 mm Hg) and in renal vascular resistance (from 0.27 ±0.03 to 0.23 ±0.02 mm Hg/ml/min) were also ameliorated compared with the control responses. Intravenous infusion of 2.5 ng/kg/min angiotensin II restored mean arterial pressure and potentiated the natriuretic and renal vascular responses to atrial natriuretic peptide 101-126. In two additional groups of anesthetized dogs, enalaprilat did not produce the profound hypotension and did not affect the natriuretic responses to atrial natriuretic peptide 101-126. When renal vascular resistance was elevated by intrarenal infusion of angiotensin II in enalaprilat-treated dogs, the natriuretic response was improved. In comparison, increases in renal vascular resistance or mean arterial pressure by intrarenal or intravenous infusion of methoxamine did not change the natriuresis induced by atrial natriuretic peptide 101-126. In conclusion, blockade of the endogenous renin-angiotensin system did not affect the natriuretic response to atrial natriuretic peptide 101-126 when perfusion pressure was maintained. Nevertheless, both intravenous and intrarenal angiotensin II potentiated the renal response to atrial natriuretic peptide 101-126 by some unique mechanism. (Circulation Research 1988;62:506-514) From the
N umerous studies have demonstrated that atrial natriuretic peptides (ANP) increase sodium excretion, lower mean arterial pressure (MAP), and suppress the renin-angiotensin system in both conscious and anesthetized dogs. 1 " 7 Since angiotensin II (ang II) produces vasoconstriction and enhances sodium reabsorption, 8 the depressor and natriuretic effects of ANP may be due in part to the reduction in endogenous renin levels. Such an interaction would be consistent with the observations that, compared with the responses in other hypertensive models, the natriuretic responses 9 and the depressor responses 10 to acute administration of ANP were exaggerated in two-kidney, one-clip hypertensive rats, a model in which renin levels are elevated.
In the present study, the renal and systemic responses to intrarenal administration of synthetic rat ANP 101-126 were determined before and after interruption of the renin-angiotensin system by inhibition of angiotensin converting enzyme (ACE) with the acid form of enalapril, MK 422 (enalaprilat), in anesthetized dogs. After ACE inhibition, ang II levels were increased by intravenous infusion of that peptide at a dose that restored blood pressure to control levels. Since intra-venous ang II elevated both renal perfusion pressure and renal vascular resistance, a second group of dogs was studied in which the vasoconstrictor effects of ang II were restricted to the kidney by intrarenal artery infusion of ang II. The responses to ANP 101-126 measured during intrarenal and intravenous ang II administration were compared with those obtained during intrarenal and intravenous infusions of the a-adrenergic agonist, methoxamine (ME). In this way, the contribution of the renin cascade to the biological effects of ANP 101-126 was determined.
Materials and Methods
Eighteen female mongrel dogs were anesthetized with vinbarbital (50 mg/kg i.v.) and intubated with a cuffed endotracheal tube. Ventilation with room air was maintained by a respirator (Harvard, South Natick, Massachusetts). Each animal was supported in an upright position, and both kidneys were exposed via bilateral flank incisions. Following unilateral nephrectomy, a polyethylene cannula was implanted in the remaining ureter for timed collections of urine. A curved 26-gauge needle attached to a length of Silastic tubing was inserted into the renal artery to provide a route for intrarenal treatments. Patency of this catheter was maintained by infusion of saline at 0.19 ml/min. Finally, an electromagnetic flow probe (Zepeda, Seattle, Washington) was placed around the renal artery distal to the infusion catheter. Lactated Ringers' solution and creatinine dissolved in saline (50 mg/kg bolus plus 1 mg/kg/min) were administered via separate venous catheters, each at a rate of 1 ml/min beginning at least 45 minutes before any experimental measurements were made. Blood pressure was monitored on a Buxco system (Buxco Electronics, Sharon, Connecticut) via a Micron pressure transducer (Micron Instruments, Los Angeles, California) attached to one femoral artery catheter. Renal blood flow (RBF) was continuously recorded, and renal vascular resistance (RVR) was derived electronically from MAP divided by RBF. At the end of each minute during a sampling period, the average value for that minute was printed out so that the peak responses could be readily determined.
During each experiment, the responses to doses of 1, 5, 25, and 125 pmol/kg/min ANP 101-126 infused for 10 minutes each via the renal artery were measured three times. Each dose-response determination was preceded by a control sample and followed by a single recovery sample and a 1-hour stabilization period during which MAP and sodium excretion returned to baseline. When the dogs were treated with enalaprilat, ang II, or ME (according to the protocols given below), sufficient time was allowed after beginning each treatment to ensure that renal and cardiovascular functions had reached a new steady state before the ANP challenges were introduced.
During each sampling period, all hemodynamic parameters were recorded, and urine was quantitatively collected for 10 minutes. Urine collections were discontinued only long enough to change the intrarenal infusate (~ 1 minute). Each urine sample and an arterial plasma sample obtained at the midpoint of each period were later analyzed using an automated spectrophotometric assay and electrolyte concentrations with ionselective electrodes (Technicon Instruments, Tarrytown, New York) to determine creatinine levels. Renal clearances of creatinine were calculated as estimates of glomerular filtration rate (GFR), and fractional electrolyte excretions were derived using standard formulas. In the first group of dogs, an additional arterial blood sample was drawn during the final minute of each observation period, and the plasma was stored for later determination of plasma renin activity (PRA) by radioimmunoassay.
In all animals, the pressor response to 0.1 p.g/kg i.v. angiotensin I was obtained before and period ical ry after the administration of enalaprilat. Before ACE inhibition, the pressor response to the angiotensin I challenge averaged 36 ± 2 mm Hg in the 18 dogs used in the three studies. At the end of the experimental protocol (approximately 5-6 hours later), angiotensin I increased MAP by only 6 ± 1 mm Hg, indicating adequate ACE inhibition.
Intravenous Angiotensin II Infusions in Dogs Treated With Enalaprilat
The first series of ANP 101-126 challenges were delivered to six untreated dogs. Approximately 45 minutes after collection of a single recovery sample, 3 mg/kg enalaprilat was injected intravenously. When blood pressure and RBF had stabilized, the ANP 101-126 treatments were repeated. Ang II was then infused intravenously at 2.5 ng/kg/min, and the responses to a third series of ANP 101-126 doses were obtained.
Intrarenal Angiotensin II Infusions in Enalaprilat-Treated Dogs
In six of the remaining dogs, the three series of ANP 101-126 treatments were delivered after administration of 3 mg/kg i.v. enalaprilat, during intrarenal infusion of 0.5 ng/kg/min ang II, and then during intrarenal infusion of 1 ng/kg/min ang II (n = 5 because of technical difficulties in one dog). For each intrarenal infusion, ANP 101-126 and ang II were combined and administered as a single solution delivered at a rate of 0.19 ml/min.
Intrarenal and Intravenous Methoxamine Treatments in Enalaprilat-Treated Dogs
The six remaining dogs were treated with enalaprilat before the first series of ANP 101-126 challenges. Before the second determination of the responses to ANP 101-126, ME was infused via the renal artery at 0.5-1 ^g/kg/min so that baseline RVR was elevated to a level comparable to that measured before enalaprilat without affecting MAP. Before the final series of ANP 101-126 challenges, ME was added to the creatinine solution so that doses of 1-2 u,g/kg/min were infused intravenously at 1 ml/min until MAP returned to the level measured before enalaprilat treatment (~ 120 mm Hg). Once MAP had stabilized, the dose of ME was held constant, and the four doses of ANP 101-126 were administered.
Data Analysis
Data are presented as the mean±SEM. Significant differences between the control values and each dose of ANP 101-126 were detected by analysis of variance for repeated measures and application of Dunnett's t test." Comparisons among the ANP 101-126 doseresponse curves were accomplished by analysis of variance and the Newman-Keuls test for differences among means.
Synthetic rat ANP 101-126, enalaprilat, and vinbarbital were synthesized at Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania. Angiotensin I and II were purchased from Sigma Chemical, St. Louis, Missouri. ME was the generous gift of Burroughs-Wellcome, Research Triangle Park, North Carolina.
Results

Intravenous Angiotensin II in Dogs Treated With Enalaprilat
To facilitate comparisons among treatment groups in which control fractional sodium excretion (FEjJ and RVR varied, the natriuretic and renal vascular responses are shown as the changes from baseline values. Under basal conditions, ANP 101-126 progressively increased FE^ from 1.8±0.6% to a peak response of 5.1 ±0.9% (/?<0.05) during delivery of 25 pmol/kg/min. At 125 pmol/kg/min, the natriuresis was slightly attenuated (Figure 1 ). ANP 101-126 progressively reduced MAP (Table 1 ) and lowered RVR from a control level of 0.40 ±0.02 to 0.30 ±0.02 mm Hg/ml/min during infusion of 125 pmol/kg/min ( Figure 1 ).
Although enalaprilat had no significant effect on FE,,, measured before ANP 101-126 (2.2 ±0.7%), the natriuretic responses to all doses of the peptide were abolished ( Figure 1 ). ACE inhibition reduced basal MAP from 106 ± 2 to 86 ± 4 mm Hg and RVR from 0.39 ±0.03 to 0.27 ±0.03 mm Hg/ml/min. Only the highest dose of ANP 101-126 slightly but significantly lowered MAP to 76 ± 4 mm Hg and RVR to 0.23 ± 0.02 mm Hg/ml/min ( Figure 1 ).
During intravenous ang II infusion, FE,,, (2.4 ± 0.6%) was not significantly different from measurements made before or after enalaprilat. Nevertheless, ANP 101-126 induced a significantly greater natriuresis during intravenous ang II infusion than under either of the other experimental conditions tested ( Figure 1 ). Ang II infusion also restored MAP to its initial value (118 ±4 mm Hg), elevated RVR to 0.65 ±0.08 mm Hg/ml/min, and enhanced the renal vasodilatory responses to ANP 101-126 ( Figure 1 ).
Baseline RBF was significantly increased by enalaprilat and later diminished by ang II infusion (Table 1) . Under all conditions, RBF increased to its peak within the first 5 minutes after beginning infusion of each dose of ANP 101-126. RBF remained within 10 ml/min of that maximal level throughout the remainder of each infusion period. Neither enalaprilat nor ang II affected GFR either before or during ANP 101-126 administration (Table 1) .
ANP 101-126 significantly reduced PRA during the basal state (Table 1) . As expected, enalaprilat increased baseline PRA, a rise that persisted during subsequent ANP 101-126 treatment. Although ANP 101-126 diminished PRA in the presence of ang II, it was not possible to determine whether the two peptides acted independently or synergisticalry to diminish renin release because of the complexity of the experimental conditions. Because the components of the reninangiotensin system were regulated by blockade or infusion of ang II in subsequent experiments, PRA measurements were not pursued.
Intrarenal Infusion of Angiotensin II in Enalaprilat-Treated Dogs
In the animals that later received intrarenal ang II infusion, baseline FEN, was 2.2 ±0.7% before and 2.9 ± 0.4% after enalaprilat. Intrarenal infusions of 0.5 and 1 ng/kg/min ang II decreased baseline FE^ to 2.1 ± 0.5% and 1.4 ± 0.2%, respectively. Despite these reductions in beginning FEu, levels, increasing the concentration of intrarenal ang II from 0 (vehicle) to 0.5 and 1 ng/kg/min improved the natriuretic responses to 25 and 125 pmol/kg/min ANP 101-126 ( Figure 2 ). Enalaprilat reduced basal RVR from 0.65 ±0.06 to 0.53 ±0.07 mm Hg/ml/min. Subsequent intrarenal infusions of 0.5 and 1 ng/kg/min ang II raised baseline renal vascular resistance to 0.83 ± 0.12 and 1.18 ± 0.10 mm Hg/ml/min, respectively. The reductions in RVR induced by ANP 101-126 were not changed by infusion of 0.5 ng/kg/min ang II ( Figure 2 ) but were potentiated by 1 ng/kg/min intrarenal ang II.
Enalaprilat did not significantly affect MAP, which was 109 ± 7 and 101 ± 9 mm Hg before and after treatment, respectively. Subsequent intrarenal infusion of ang II did not alter baseline MAP (compare the values listed in Table 2 , first column), indicating that the vascular effects of this peptide were apparently restricted to the kidney under basal conditions. In addition, intrarenal ang II administration did not affect the systemic depressor responses to increasing doses of ANP 101-126 ( Table 2 ). The depressor effect was still evident 10 minutes after ending the highest ANP dose during all treatments studied (Table 2, last column).
Enalaprilat pretreatment produced statistically insignificant changes in RBF (from 174 ± 26 to 210 ± 44 ml/min), GFR (from 24 ±2 to 22 ±1 ml/min) and filtration fraction (from 25 ±2 to 21 ±3%). In addition, the ensuing ANP 101-126 infusions did not significantly affect any of these parameters. Later intrarenal ang II infusions significantly lowered basal renal blood flow without affecting GFR ( Table 2) . As a consequence, baseline filtration fraction increased from 21 ±3% (measured during vehicle infusion) to 31 ± 4% during treatment with 0.5 ng/kg/min of ang II and to 37 ±3% during delivery of 1 ng/kg/min. Even though ANP 101-126 treatment significantly elevated RBF during intrarenal infusions of 0.5 and 1 ng/kg/min ang II, GFR was not altered so that filtration fraction fell to 23 ±2% and 27 ±2%, respectively.
Methoxamine in Enalaprilat-Treated Dogs
Neither enalaprilat nor addition of intrarenal ME significantly affected baseline FEN, (1.3 ±0.3%, 1.4±0.3%, and 1.2±0.3% initial level, after enalaprilat and during intrarenal ME, respectively), while intravenous ME elevated baseline FE,,, to 2.8 ±0.4%. Under all three experimental conditions, ANP 101-126 significantly increased FE,,, (Figure 3 ). The peak natriuresis was achieved during administration of 25 pmol/kg/min ANP 101-126 to dogs pretreated with enalaprilat and during intravenous ME; however, 125 pmol/kg/min ANP 101-126 was most effective during intrarenal ME infusion.
Enalaprilat initially lowered baseline RVR from 0.70 ±0.04 to 0.60 ±0.04 mm Hg/ml/min and MAP from 109 ± 2 to 102 ± 3 mm Hg but did not prevent the systemic or renal vasodilatory responses to ANP 101-126 ( Figure 3 and Table 3 ). Intrarenal infusion of ME raised RVR to a level (0.77 ±0.08 mm Hg/ml/min) approximately that measured before enalaprilat administration without affecting MAP. The a-adrenergic agonist also appeared to counter the vasodilatory responses to ANP 101-126 since the decreases in RVR and MAP were greatly attenuated ( Figure 3 and Table 3 ).
MAP fell insignificantly from 109 ± 2 to 102 ± 3 mm Hg after enalaprilat administration. Intravenous ME delivery significantly increased baseline MAP to a value not significantly different from that measured before enalaprilat (Table 3) . RVR was concurrently elevated to 0.87 ±0.11 mm Hg/ml/min, a level not significantly different from that measured during intrarenal ME administration. Despite changes in baseline conditions, subsequent ANP 101-126 treatment produced changes in MAP, RVR, and FE^ parallel to those measured immediately following enalaprilat treatment ( Table 3 and Figure 3 ).
Enalaprilat did not significantly affect baseline RBF (156 ± 8 and 172 ± 10 ml/min before and after, respectively) or the vasodilatory responses to subsequent administration of ANP 101-126 (Table 3 ). ME administered either intrarenal ry or intravenously significantly lowered baseline renal blood flow to 137 ±12 and 143 ± 12 ml/min, respectively, and attenuated the flow responses to ANP 101-126 (Table 3) .
Neither enalaprilat nor intravenous ME significantly altered basal GFR or filtration fraction (Table 3) . However, intrarenal ME significantly reduced GFR without affecting filtration fraction, effects that were in direct contrast to those produced by intrarenal ang II. Even in the presence of this variety of starting conditions, ANP 101-126 infusions did not significantly affect GFR or filtration fraction following enalaprilat alone or during intravenous or intrarenal ME (Table 3) .
In all three series of experiments, fractional excretion of potassium and chloride tended to rise in concert with the natriuretic responses to ANP 101-126. The diuretic profile was also similar to the pattern of natriuresis induced by ANP 101-126 except in those dogs that received intrarenal ang II treatment (Tables  1-3 ). In the latter dogs, intrarenal ANP 101-126 infusions did not enhance the rise in urine volume ( Table 2 ) despite the greater natriuretic response. In all studies, plasma sodium and chloride concentrations were unaffected by ANP 101-126, while plasma potassium levels fell in a dose-related manner.
The results of the present studies may be best summarized by comparing the natriuretic responses to 25 pmol/kg/min ANP 101-126 under each experimental condition as outlined in Table 4 . (The natriuretic response to 25 pmol/kg/min ANP 101-126 obtained during infusion of 1 ng/kg/min ang II [7.2 ± 3.8%] was not significantly different from that achieved with 0.5 ng/kg/min and was omitted from the table for the sake of clarity.) The effects of ACE inhibition alone in the three groups of dogs may be ascertained by inspection of the responses labeled as MK 422. The natriuretic response to 25 pmol/kg/min ANP 101-126 was significantly diminished (compared with the saline-treated animals) only in the group of dogs in which MAP was reduced to 82 ± 3 mm Hg. Even though reduction in endogenous activity of the renin-angiotensin system did not appear to importantly diminish the natriuretic effect of ANP 101-126 when the perfusion pressure was maintained, intravenous ang II potentiated the response. Since the same improvement was not attained during intravenous ME despite identical MAP (Table  4) , maintenance of perfusion pressure alone did not explain the ang II potent iat ion of the renal effects of ANP 101-126.
Additional evidence that the ang II potentiation was not mediated simply by maintaining MAP was gathered from the experiments in which ang II was administered intrarenal ry. At a MAP comparable with that measured in two groups of anesthetized dogs treated with enalaprilat (Table 4) , intrarenal ang II potentiated the natriuretic responses to ANP 101-126. Even in the dogs receiving 1 ng/kg/min ang II in which ANP 101-126 reduced MAP to 85 ± 11 mm Hg, a condition that had completely blocked the natriuretic effect in enalaprilattreated dogs, ¥E^ was elevated (7.2±3.8%). The lower perfusion pressure may account for the greater variability found in the latter group. In addition, the enhanced natriuresis appeared unique to ang II because intrarenal ME increased basal RVR to a level similar to that achieved with 0.5 ng/kg/min ang II and, despite equivalent perfusion pressures, did not improve FE (  Table 4 ).
Discussion
A number of investigators have reported that synthetic ANP simultaneously increases sodium excretion and suppresses renin secretion and aldosterone pro- IRA, intrarenal; AFE Ni , fractional sodium excretion; MAP, mean arterial pressure; IV, intravenous; Ang II, angiotensin II; ME, methoxamine; group 1, dogs in which ANP 101-126 responses were obtained during saline treatment, after MK 422 and during intravenous Ang D; group 2, dogs in which ANP 101-126 responses were obtained after MK 422 and during intrarenal Ang II infusion at 0.5 ng/kg/min; group 3, dogs in which ANP 101-126 responses were obtained after MK 422, during intrarenal ME, and during intravenous ME; AFEN,, difference between baseline fractional sodium excretion and FEN, measured during infusion of 25 pmol/kg/ min ANP 101-126. *p<0.05 compared with saline-treated dogs.
duction despite a concurrent reduction in MAP in anesthetized and conscious dogs. 1 " 7 Because the effectors of the renin-angiotensin-aldosterone cascade (ang II and aldosterone) produce vasocohstriction and enhance tubular sodium reabsorption, lowering the endogenous activity of the renin system could contribute to the cardiovascular and renal responses.to ANP. Indeed, the depressor, adrenal, 10 and natriuretic 9 responses to ANP were enhanced in two-kidney, one-clip hypertensive rats, a model characterized by increased renin activity.
In the present study, several approaches were used to determine the importance of the renin-angiotensin system to the natriuretic and depressor responses to ANP 101-126 in anesthetized dogs. In the first experiment, we confirmed that doses of 1, 5, 25, and 125 pmol/kg/min intrarenal ANP 101-126 increased FEN, in anesthetized one-kidney dogs. Subsequent treatment with enalaprilat abolished both the depressor and the natriuretic responses to all concentrations of ANP 101-126. However, because enalaprilat alone reduced MAP to 86 ± 1 0 mm Hg, a condition known to attenuate the renal responses to ANP, 12 " 15 we could not conclude that inhibition of the renin-angiotensin system per se was responsible for the effects of enalaprilat. Nevertheless, a role for the renin cascade was indicated by the finding that ang II replacement via intravenous infusion enhanced the natriuretic effects of ANP 101-126. Because the selected dose of ang II not only restored MAP to its initial baseline level but also elevated RVR, it was possible that ang II may have improved the natriuretic capacity of ANP by actions that were related to nonspecific hemodynamic effects and were not unique to the renin-angiotensin system. To investigate the mechanism by which ang II potentiated the responses to ANP 101-126, enalaprilat was administered to two groups of dogs that had received no prior treatment. Converting enzyme inhibition tended to lower MAP in these animals, but baseline MAP did not fall lower than 100 mm Hg, a pressure previously shown to allow ANP to produce a natriuretic response in either group. 12 Clearly, the profound hypotension observed in the first experiment did not occur. This difference may be explained by the differences in protocols. In the first series of experiments, the dogs received enalaprilat after the first dose-response curve for ANP 101-126 had been obtained. Although ANP itself reduces renin activity", there may have been a rebound increase in renin once ANP was withdrawn. In the other two groups of dogs, enalaprilat was administered before any other experimental intervention, so there was less likelihood that renin levels were elevated. More important, the natriuretic and depressor responses to ANP 101-126 were not compromised by enalaprilat. Therefore, blockade of endogenous formation of ang II did not affect the activity of ANP when renal perfusion pressure was maintained. These findings are consistent with the observation that ANP produced natriuresis and vasodilation in isolated perfused kidneys, 1617 a system in which renin activity is suppressed by the deficiency of angiotensinogen.
In addition, our results agree with the independent finding in anesthetized rats 18 that saralasin, an ang II antagonist, did not affect the changes in renal hemodynamics induced by ANP 103-126 infused intravenously at a higher dose than those used in the present experiments. Despite the differences in the species studied, in the sequences of the atrial peptides infused, and in the route of administration, those investigators also failed to show any effect of blockade of the renin cascade on the natriuretic response to ANP. Both the results given in the present study and by Dunn et al 18 differ from those of a third study in which captopril was found to increase the natriuretic response to extracts of monkey atria in anesthetized rats." Unfortunately, there was not sufficient data given to determine the reason for that discrepancy.
In the present study, the intrarenal interactions of ang II and ANP were investigated further. To accomplish this goal, the effects of ang II were confined to the kidney by infusing that peptide intrarenalry at doses that elevated RVR without changing systemic blood pressure. Intrarenal ang II infusions improved both the natriuretic and the renal vasodilatory responses to ANP 101-126, even when MAP fell below 85 mm Hg, a condition that normally attenuates natriuresis. 12 " 15 In a previous study of isolated perfused rat kidneys, atrial extracts produced natriuresis and a slight increase in renal vascular resistance. 16 When a vasoconstrictor, such as ang II, norepinephrine, or vasopressin, was added to the perfusate, basal vascular resistance was elevated, and atrial extracts induced a vasodilatory response. Although the natriuretic effects of ANP during addition of those vasoconstrictors were not reported, the authors concluded that the active component of the atrial extract antagonized vasoconstrictors that are normally present in intact animals. In the present study, there was no evidence that pure, synthetic ANP 101-126 produced vasoconstriction in kidneys of anesthetized dogs when the reninangiotensin cascade was interrupted by enalaprilat treatment. Furthermore, intrarenal administration of 0.5 ng/kg/min ang II potentiated the natriuretic responses to ANP 101-126 but had no effect on the renal vasodilatory responses despite an increase in baseline RVR. Interestingly, increasing the dose of ang II to 1 ng/kg/min did not yield any further improvement of the natriuretic response to ANP 101-126 even though baseline RVR was raised to a still higher level and the renal vasodilatory response was significantly improved. These findings indicated that intrarenal ang II enhanced ANP-induced natriuresis in a manner not directly related to its vasoconstrictor effect.
That conclusion was strengthened by the results of the studies in which ME was infused intrarenalry or intravenously into dogs pretreated with enalaprilat. Intrarenal ME delivery increased basal RVR without affecting MAP, conditions that were indistinguishable from those produced by 0.5 ng/kg/min intrarenal ang II. Despite the similarity of the vasoconstrictor effects of the two agents, intrarenal ME did not potentiate the natriuretic responses to ANP 101-126. Instead, the renal vasodilatory responses were blunted, and the natriuretic dose-response curve was shifted down and to the right.
Furthermore, intravenous ME elevated MAP and RVR to levels similar to those achieved during intravenous infusion of ang II. Unlike the improvement of the ANP responses obtained with intravenous ang II, systemic ME administration had no effect on the natriuretic or the depressor responses to ANP 101-126. Ang II therefore appears to potentiate the ANP response by some mechanism other than general vasoconstriction or maintenance of MAP.
The unique effect of ang II could possibly be related to a preferential constriction of the efferent arteriole by that peptide. 20 In the present studies, 0.5 ng/kg/min intrarenal ang II altered renal hemodynamics in a manner consistent with a preferential rise in efferent arteriolar resistance; that is, renal blood flow was reduced without affecting GFR so that filtration fraction increased. Furthermore, ME produced changes that may be expected when afferent arteriolar constriction predominates (decreases in both GFR and RBF with no change in filtration fraction). Despite these differences in baseline renal hemodyamics, there were no differences in GFR (18 ± 2 and 19 ± 2 ml/min), filtration fraction (23% and 24%), or RBF (151 ± 3 8 and 163 ± 1 6 ml/min) during administration of 25 pmol/kg/min ANP 101-126 in dogs receiving ang II and ME, respectively. There was, however, a significantly better natriuretic response to ANP 101-126 during intrarenal ang II infusion (6.1 ±1.4%) than during intrarenal ME administration (2.5 ±0.5%). Because any discrepancies in MAP (94 ± 10 mm Hg during ang II treatment versus 104 ± 4 mm Hg during ME) would not favor a greater natriuresis in the animals treated with ang II, some mechanism other than hemodynamic effects appears likely.
ANP has been shown to inhibit aldosterone production, 2122 an effect that could elevate FE^,. Should the ang II treatments used in the present experiments increase basal concentrations of plasma aldosterone, subsequent reductions in aldosterone levels by ANP could explain the exaggerated natriuretic response. Because plasma aldosterone concentrations were not measured in the present study, this possibility cannot be discounted.
Alternatively, ANP may interact with ang II at a tubular site to enhance sodium excretion. Ang II has been shown to stimulate sodium reabsorption in the proximal tubule 8 ; interruption of that process by ANP would promote natriuresis. The possibility of a direct effect appears rather unlikely because there is little evidence that ANP has any direct activity in that segment 2 *" 25 and ANP did not directly oppose the biological responses to ang II in any of several target cells. 26 In summary, inhibition of ACE did not compromise the renal responses to ANP 101-126 when renal perfusion pressure was maintained. Subsequent administration of ang II, but not ME, either intravenously or intrarenalry, enhanced the ANP-induced natriuresis. The potentiation of the natriuretic responses was not directly related to the baseline level of RVR or to the magnitude of the vasodilatory responses. In conclusion, ang II improved the natriuretic capacity of ANP 101-126 by some mechanism that was at least in part independent of its vasoconstrictor activity.
